Late Stage Science Lead CKD @ From September 2015 to Present (4 months) Biomarker & EM Leader, Ophthalmology @ Senior principal scientist responsible for delivering biomarkers for stratifying patient populations, as well as target-specific mechanistic and pharmacodynamic biomarkers to aid drug development. Leading the set-up and development of an overarching enabling biomarker and translational strategy for ophthalmology
Late Stage Science Lead CKD @ From September 2015 to Present (4 months) Biomarker & EM Leader, Ophthalmology @ Senior principal scientist responsible for delivering biomarkers for stratifying patient populations, as well as target-specific mechanistic and pharmacodynamic biomarkers to aid drug development. Leading the set-up and development of an overarching enabling biomarker and translational strategy for ophthalmology diseases, from drug delivery through to stratified medicine.
Responsible for developing a translational chain of in vitro and animal model data through focus on relating experimental tools to human targets, pathways and tissues in ophthalmic disease. From February 2014 to July 2015 (1 year 6 months) Basel Area, SwitzerlandBiomarker & EM Leader, Renal Diseases @ Principal scientist responsible for setting, developing and implementing biomarker strategies and deliverables for both small molecule and biologics projects in multiple CVM therapeutic areas, with a focus on acute and chronic renal complications.
Leading the development of PD biomarker strategy, designing and implementing biomarker assets to support projects and enable key decisions throughout the clinical development. From February 2012 to January 2014 (2 years) Basel Area, SwitzerlandBiomarker & EM Leader, Metabolism & Vascular Disease area @ Leading the discovery, development, validation efforts for appropriate utilization of biomarkers and diagnostic tools throughout the drug development, with the major aim of enabling the translation and clinical validation of new pharmaco-dynamic and predictive biomarkers in clinical trials practice.
Responsible for the identification and validation of novel targets/biomarkers, investigation of the drug mechanism of action and underlying pathways, identification of early efficacy markers, characterization of disease (sub)populations, prediction of treatment response (personalized medicine) utilizing interventional and non-interventional experimental medicine studies and technologies.
Responsible for the generation & implementation of detailed translational science strategic plans for the designated projects and for broadening the biomarker knowledge in the disease area.
Responsible for the appropriate utilization of biomarkers and diagnostic tools during drug development, the support of the clinical development plan with understanding of selection of the right molecular biomarker platform (e.g. IHC, gene expression profiling, genotyping, immunoassays, -omics approaches, etc.)
Accountable for supporting the development of pathway, disease and translational disease models integrating target biology /pathways/ disease knowledge and candidate properties.
Responsible for establishing collaborations with internal and external academic or industry based experts to design and oversee interventional and non-interventional studies with primary endpoints related to understanding of disease pathogenesis, characterizing disease (sub)populations, predicting treatment response and development of BM and Dx assays. From September 2009 to February 2012 (2 years 6 months) Basel Area, SwitzerlandPostdoctoral fellow @ Senior postdoctoral fellow at the Institute of Cell Biology in the lab of Romeo Ricci
Main research project:
-Signal transduction pathways underlying cellular pathomechanisms of the metabolic syndrome with a particular focus on the stress-induced Mitogen-Activated Protein Kinase (MAPK) signaling cascade
-Regulation of pancreatic β cell function and glucose homeostasis by the MAPK p38δ.
-Regulation of neutrophil function by the MAPK p38δ. From November 2006 to August 2009 (2 years 10 months) PhD student @ PhD project focused on understanding how the Ras-MAPK signal transduction pathway affects normal and pathological behavioral plasticity in neurons and influences learning and memory in different brain structures. From 2003 to 2006 (3 years) Project manager @ Junior scientific officer, technical support manager and product manager life science at Adaltis S.p.A From 2002 to 2003 (1 year) Research associate @ Department of Immunology, Intervet BV, Boxmeer, The Netherlands.
Research focused on the development of in vivo DNA vaccination approaches against O. rhinotracheale. The aim was to identify cross-protective antigens to be use as a multi-component vaccine. Advisor: Piet M.J. Nuijten, Ph.D. From 1999 to 2000 (1 year)
PhD, Molecular Medicine @ Libera Università Vita-Salute San Raffaele From 2003 to 2006 biotechnology @ Università di Bologna From 1996 to 2002 Ivan Formentini is skilled in: Biomarkers, Clinical Development, Clinical Trials, Drug Development, Genetics, In Vitro, Molecular Biology, Biochemistry, Biotechnology
Looking for a different
Get an email address for anyone on LinkedIn with the ContactOut Chrome extension